PDE4A and Behcet disease: It was the inaugural PDE4 inhibitor to receive Food and Drug Administration (FDA) approval for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, and Behcet’s disease in 2014 [37].